Thomas Reiner

Thomas Reiner has an extensive work experience in the field of scientific research and oncology. Thomas is currently serving as the Chief Scientific Officer at Evergreen Theragnostics since December 2022. Prior to this, they worked at Novartis Institutes for BioMedical Research (NIBR) as the Executive Director, Radioligand Therapy Lead from July 2021 to November 2022.

Before joining NIBR, Thomas Reiner was associated with Memorial Sloan Kettering Cancer Center for a significant period. Thomas held the positions of Associate Member, Associate Professor from March 2017 to July 2021, and Assistant Member, Assistant Professor from June 2012 to September 2017.

Thomas Reiner started their career as an Instructor at Harvard Medical School and Massachusetts General Hospital from November 2011 to May 2012. Prior to this, they served as a Leopoldina Foundation Postdoctoral Research Fellow from July 2009 to October 2011.

Thomas Reiner began their education in 2001 at the Technical University of Munich, where they earned a Bachelor of Science degree in Chemistry in 2005. Thomas continued their studies at the same institution, completing a Master of Science degree in Chemistry in 2006. From 2006 to 2009, Thomas pursued a Doctor of Philosophy degree at the Technical University of Munich, specializing in Chemistry.